Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that it has been shortlisted as a finalist in the 2018 OBN awards in the category “Best Emerging Biotech Company”.
These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry. The OBN’s “Best Emerging Biotech Company” award goes to a company which has:
- Evidence of a credible product pipeline
- Proof of significant clinical trial activity
- Made an impact on the industry via significant news flow
- Proof of continued fundraising
- Evidence of a strong team in place
- Proof of developing partnerships and collaborations
- Clear evidence of a robust business plan to support continued growth
- Been incorporated in the UK after 2013 but before 1 June 2016
Blue Earth Diagnostics, which was formed in 2014, is focused on the development and commercialization of novel positron emission tomography (PET) imaging agents to inform clinical management and guide care for patients with cancer. The company, which has its headquarters in Oxford, UK, and a US office in Burlington, MA, has over 60 employees and is led by a team of recognized experts in the clinical development and commercialization of innovative nuclear medicine products.
Dr. Jonathan Allis, the founding CEO of Blue Earth Diagnostics commented, “We’re delighted to receive the industrywide recognition that being shortlisted for this prestigious award brings. We’re on a mission to help improve the lives of people with cancer by developing and bringing to market innovative imaging agents that both inform and guide patient care. Receiving this nomination is both an honour for our whole team and a great endorsement of Blue Earth’s progress over the last four years.”
Dr. John Harris, CEO of OBN (UK) said: “We received the highest number of qualifying entries for the OBN Awards this year, up a staggering 40% on last years’ total. The standard of entries across all categories was extremely high and we are encouraged about the level of exciting new innovation and positive growth we are seeing in UK Life Sciences. We look forward to celebrating with all our finalists on 11 October at the Examination Schools in Oxford.”
About Blue Earth Diagnostics Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.
PP--UK-0093 / August 2018
About OBN The OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities. For more information please visit: www.obn.org.uk.